Login / Signup

Hepatoprotective Effect of Silymarin (Silybum marianum) on Hepatotoxicity Induced by Acetaminophen in Spontaneously Hypertensive Rats.

Abel Felipe FreitagGabriel Fernando Esteves CardiaBruno Ambrósio da RochaRafael Pazzinatto AguiarFrancielli Maria de Souza Silva-ComarRicardo Alexandre SpironelloRenata GrespanSilvana Martins Caparroz-AssefCiomar Aparecida Bersani-AmadoRoberto Kenji Nakamura Cuman
Published in: Evidence-based complementary and alternative medicine : eCAM (2015)
This study was aimed to investigate the effect of Silymarin (SLM) on the hypertension state and the liver function changes induced by acetaminophen (APAP) in spontaneously hypertensive rat (SHR). Animals normotensive (N) or hypertensive (SHR) were treated or not with APAP (3 g/kg, oral) or previously treated with SLM. Twelve hours after APAP administration, plasmatic levels of liver function markers: alanine aminotransferase (ALT), aspartate aminotransferase (AST), glucose (GLU), gamma glutamyl transferase (γ-GT), and alkaline phosphatase (ALP) of all groups, were determined. Liver injury was assessed using histological studies. Samples of their livers were then used to determine the myeloperoxidase (MPO) activity and nitric oxide (NO) production and were also sectioned for histological analysis. No differences were observed for ALT, γ-GT, and GLU levels between SHR and normotensive rats groups. However, AST and ALP levels were increased in hypertensive animals. APAP treatment promoted an increase in ALT and AST in both SHR and N. However, only for SHR, γ-GT levels were increased. The inflammatory response evaluated by MPO activity and NO production showed that SHR was more susceptible to APAP effect, by increasing leucocyte infiltration. Silymarin treatment (Legalon) restored the hepatocyte functional and histopathological alterations induced by APAP in normotensive and hypertensive animals.
Keyphrases
  • liver injury
  • drug induced
  • blood pressure
  • nitric oxide
  • inflammatory response
  • adipose tissue
  • combination therapy
  • lipopolysaccharide induced
  • metabolic syndrome
  • newly diagnosed